PRESS RELEASE REGULATED INFORMATION 5 August 2024, 06 pm CEST Ghent, Belgium – 5 August 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that it received a transparency notification from the party listed...Read More
PRESS RELEASE REGULATED INFORMATION 1 August 2024, 06:30 pm CEST Ghent, Belgium – 1 August 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that it received a transparency notification from the parties listed...Read More
Transparency Notifications from Shareholders Ghent, Belgium – 19 July 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that it received a transparency notification from the shareholder listed below, notifying the number of voting...Read More
PRESS RELEASE REGULATED INFORMATION 10 July 2024, 06:00 p.m. CEST Ghent, Belgium, 10 July 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that in the context of the confirmation of the contribution in...Read More
PRESS RELEASE REGULATED INFORMATION 5 July 2024, 06:00 p.m. CEST Ghent, Belgium, 5 July 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that in the context of (i) a subscription to new shares...Read More
PRESS RELEASE REGULATED INFORMATION 6 JUNE, 2024, 07.00 CEST Sequana Medical announces data on alfapump® safety and quality of life to be presented at EASL Congress 2024 “alfapump implantation significantly improved quality of life and showed similar safety outcomes compared to a contemporaneously enrolled refractory ascites cohort”;oral poster presentation by Dr. Bajaj Matched cohort analysis...Read More
PRESS RELEASE REGULATED INFORMATION 23 May 2024, 06:00 pm CEST Ghent, Belgium – 23 May 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces that all proposed resolutions submitted to the Annual and Extraordinary...Read More
PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION 22 MAY 2024, 07:00 CEST Positive and collaborative meeting with FDA PMA substantive review complete; No further new questions on clinical or pre-clinical data FDA Advisory Panel no longer expected FDA Marketing Approval now anticipated in Q1 2025 Planned US commercial launch remains H2 2025 Ghent, Belgium –...Read More
PRESS RELEASE REGULATED INFORMATION 23 April 2024, 07:00 am CET Publication of Annual Report 2023Ghent, Belgium – 23 April 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today invites the holders of securities issued by...Read More
PRESS RELEASE Regulated information 11 April 2024, 06:00 pm CEST Ghent, Belgium – 11 April 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announces today that it received transparency notifications from the shareholders listed below,...Read More